1. Home
  2. TOVX

as 06-06-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Founded: 2001 Country:
United States
United States
Employees: N/A City: ROCKVILLE
Market Cap: 3.8M IPO Year: 2006
Target Price: N/A AVG Volume (30 days): 1.8M
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -13.25 EPS Growth: N/A
52 Week Low/High: $0.40 - $7.37 Next Earning Date: 05-14-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

TOVX Daily Stock ML Predictions

Latest Theriva Biologics Inc. News

TOVX Breaking Stock News: Dive into TOVX Ticker-Specific Updates for Smart Investing

All TOVX News

Share on Social Networks: